NKTR – nektar therapeutics (US:NASDAQ)
Stock Stats
News
3/20
06:00 pm
nktr
Low
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
3/14
08:02 am
nktr
Low
Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $6.00 price target on the stock.
3/13
12:08 pm
nktr
Low
Nektar Therapeutics (NASDAQ: NKTR) had its "market perform" rating re-affirmed by analysts at William Blair.
3/13
08:13 am
nktr
Medium
Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.50 price target on the stock.
3/12
10:37 pm
nktr
Medium
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say [Yahoo! Finance]
3/12/2025
04:15 pm
nktr
-2.9%
BEAT
3/12/2025
04:15 pm
nktr
-2.9%
BEAT
3/12/2025
04:15 pm
nktr
-2.9%
BEAT
3/12/2025
04:15 pm
nktr
-2.9%
BEAT
3/14
08:27 am
Upgrades
Perform
Outperform
Oppenheimer
Low
1.3%
3/14
08:27 am
Upgrades
Perform
Outperform
Oppenheimer
Low
1.3%
3/14
08:02 am
Upgrades
Market Perform
Outperform
Oppenheimer Holdings Inc.
Low
1.9%
3/13
06:10 pm
Upgrades
PERFORM
OUTPERFORM
OPPENHEIMER
Medium
-5.3%
3/13
06:10 pm
Upgrades
PERFORM
OUTPERFORM
OPPENHEIMER
Medium
-5.3%
4/4
04:05 pm
nktr
High
Form 8-K NEKTAR THERAPEUTICS For: Apr 03
4/2
06:02 am
nktr
Medium
Form EFFECT NEKTAR THERAPEUTICS
3/28
05:10 pm
nktr
Medium
Form 8-K NEKTAR THERAPEUTICS For: Mar 28
3/28
04:23 pm
nktr
Medium
Form S-3 NEKTAR THERAPEUTICS
3/14
04:23 pm
nktr
Low
Form S-8 NEKTAR THERAPEUTICS
Show more
Top News Gainers
1/10 Form 8-K NEKTAR THERAPEUTICS For: Jan 09 23.0%
9/9 Form 4 NEKTAR THERAPEUTICS For: Sep 05 Filed by: Doberstein Stephen K 11.5%
12/6 Form 8-K NEKTAR THERAPEUTICS For: Dec 05 10.2%
8/9 Nektar Therapeutics (NASDAQ: NKTR) had its price target lowered by analysts at BMO Capital Markets to $41.00. They now have an "outperform" rating on the stock. 10.1%
6/2 Nektar Therapeutics (NASDAQ: NKTR) was given a new $82.00 price target on by analysts at Cowen Inc. They now have a "buy" rating on the stock. 9.9%
2/28 Nektar Therapeutics (NASDAQ: NKTR) had its "outperform" rating re-affirmed by analysts at William Blair. 9.5%
5/9 Nektar Therapeutics (NKTR) Q1 2019 Earnings Call Transcript [The Motley Fool] 9.1%
11/19 Form 8-K NEKTAR THERAPEUTICS For: Nov 13 7.8%
11/7 Nektar Therapeutics (NASDAQ: NKTR) had its price target lowered by analysts at Piper Jaffray Companies from $50.00 to $35.00. They now have an "overweight" rating on the stock. 7.5%
3/13 Nektar Therapeutics (NASDAQ: NKTR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.1%
Top News Decliners
8/8 Q2/2019 6/30/2019 EPS -0.630 ZacksConsensus -0.800 ActVsEst 0.170 - Beat -29.3%
1/14 Nektar Therapeutics (NKTR) Presents At 38th Annual J.P. Morgan Healthcare Conference - Slideshow [Seeking Alpha] -16.0%
3/13 Form 4 NEKTAR THERAPEUTICS For: Mar 11 Filed by: CHESS ROBERT -13.4%
8/10 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm -11.2%
11/15 Form 4 NEKTAR THERAPEUTICS For: Nov 13 Filed by: Labrucherie Gil M -8.4%
5/15 Nektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting -7.8%
10/8 Nektar Therapeutics (NASDAQ: NKTR) was downgraded by analysts at Goldman Sachs Group Inc from a "buy" rating to a "sell" rating. They now have a $16.00 price target on the stock, down previously from $54.00. -7.5%
8/4 More Potential FDA Opioid Delays In Nektar's Wake [Seeking Alpha] -7.4%
9/26 Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Triple-Negative Breast Cancer Patients at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference -6.8%
10/1 Form 4 NEKTAR THERAPEUTICS For: Sep 27 Filed by: CHESS ROBERT -6.0%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3